

=> fil reg; d stat que l11

FILE 'REGISTRY' ENTERED AT 12:39:33 ON 30 NOV 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 28 NOV 2004 HIGHEST RN 790189-55-8

DICTIONARY FILE UPDATES: 28 NOV 2004 HIGHEST RN 790189-55-8

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004


Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:

<http://www.cas.org/ONLINE/DBSS/registryss.html>

L1 STR



NODE ATTRIBUTES:

CONNECT IS E1 RC AT 1

DEFAULT MLEVEL IS ATOM

GGCAT IS LIN HIC AT 1 *all of at node 1 is linear & has >6 carbon-*

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 6

STEREO ATTRIBUTES: NONE

L3 SCR 1830 AND 963 AND 1834

L11 53 SEA FILE=REGISTRY SSS FUL L1 AND L3

100.0% PROCESSED 239548 ITERATIONS

53 ANSWERS

SEARCH TIME: 00.00.24

=> fil capl; d que nos l16

FILE 'CAPLUS' ENTERED AT 12:39:34 ON 30 NOV 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available

for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 30 Nov 2004 VOL 141 ISS 23  
FILE LAST UPDATED: 28 Nov 2004 (20041128/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

*compound*  
+  
*cancer*

L1 STR  
L3 SCR 1830 AND 963 AND 1834  
L11 53 SEA FILE=REGISTRY SSS FUL L1 AND L3  
L13 31 SEA FILE=CAPLUS ABB=ON L11  
L15 398703 SEA FILE=CAPLUS ABB=ON ANTITUMOR AGENTS/CT OR NEOPLAS?/CW  
L16 5 SEA FILE=CAPLUS ABB=ON L13 AND L15

=> fil uspatf; d que nos l19

FILE 'USPATFULL' ENTERED AT 12:39:34 ON 30 NOV 2004  
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 30 Nov 2004 (20041130/PD)  
FILE LAST UPDATED: 30 Nov 2004 (20041130/ED)  
HIGHEST GRANTED PATENT NUMBER: US6826778  
HIGHEST APPLICATION PUBLICATION NUMBER: US2004237163  
CA INDEXING IS CURRENT THROUGH 30 Nov 2004 (20041130/UPCA)  
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 30 Nov 2004 (20041130/PD)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2004  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2004

>>> USPAT2 is now available. USPATFULL contains full text of the <<<  
>>> original, i.e., the earliest published granted patents or <<<  
>>> applications. USPAT2 contains full text of the latest US <<<  
>>> publications, starting in 2001, for the inventions covered in <<<  
>>> USPATFULL. A USPATFULL record contains not only the original <<<  
>>> published document but also a list of any subsequent <<<  
>>> publications. The publication number, patent kind code, and <<<  
>>> publication date for all the US publications for an invention <<<  
>>> are displayed in the PI (Patent Information) field of USPATFULL <<<  
>>> records and may be searched in standard search fields, e.g., /PN, <<<  
>>> /PK, etc. <<<

>>> USPATFULL and USPAT2 can be accessed and searched together <<<  
>>> through the new cluster USPATALL. Type FILE USPATALL to <<<  
>>> enter this cluster. <<<  
>>> <<<  
>>> Use USPATALL when searching terms such as patent assignees, <<<  
>>> classifications, or claims, that may potentially change from <<<  
>>> the earliest to the latest publication. <<<

This file contains CAS Registry Numbers for easy and accurate substance identification.

L1 STR  
L3 SCR 1830 AND 963 AND 1834  
L11 53 SEA FILE=REGISTRY SSS FUL L1 AND L3  
L19 4 SEA FILE=USPATFULL ABB=ON L11

*all refs. to compound*

=> fil biosis toxcenter anabs; d que nos 125

FILE 'BIOSIS' ENTERED AT 12:39:35 ON 30 NOV 2004  
Copyright (c) 2004 The Thomson Corporation.

FILE 'TOXCENTER' ENTERED AT 12:39:35 ON 30 NOV 2004  
COPYRIGHT (C) 2004 ACS

FILE 'ANABSTR' ENTERED AT 12:39:35 ON 30 NOV 2004  
COPYRIGHT (c) 2004 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

L1 STR  
L3 SCR 1830 AND 963 AND 1834  
L11 53 SEA FILE=REGISTRY SSS FUL L1 AND L3  
L20 17 SEA L11  
L21 874037 SEA ?CANCER?  
L22 1136713 SEA ?NEOPLAS?  
L23 1465382 SEA ?TUMOR? OR ?TUMOUR?  
L24 281732 SEA ?MALIGNAN?  
L25 11 SEA L20 AND (L21 OR L22 OR L23 OR L24)

*compound  
+  
cancer*

=> fil IMSDRUGNEWS, IMSRESEARCH, PROUSDDR; d que nos 128

FILE 'IMSDRUGNEWS' ENTERED AT 12:39:36 ON 30 NOV 2004  
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'IMSRESEARCH' ENTERED AT 12:39:36 ON 30 NOV 2004  
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'PROUSDDR' ENTERED AT 12:39:36 ON 30 NOV 2004  
COPYRIGHT (C) 2004 Prous Science

*all refs to compound*

L1 STR  
L3 SCR 1830 AND 963 AND 1834  
L11 53 SEA FILE=REGISTRY SSS FUL L1 AND L3  
L28 4 SEA L11

=> dup rem 116,119,125,128

DUPLICATE IS NOT AVAILABLE IN 'IMSRESEARCH, PROUSDDR'.  
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE  
FILE 'CAPLUS' ENTERED AT 12:39:37 ON 30 NOV 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 12:39:37 ON 30 NOV 2004  
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 12:39:37 ON 30 NOV 2004  
Copyright (c) 2004 The Thomson Corporation.

FILE 'TOXCENTER' ENTERED AT 12:39:37 ON 30 NOV 2004  
COPYRIGHT (C) 2004 ACS

FILE 'ANABSTR' ENTERED AT 12:39:37 ON 30 NOV 2004  
COPYRIGHT (c) 2004 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'IMSDRUGNEWS' ENTERED AT 12:39:37 ON 30 NOV 2004  
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'IMSRESEARCH' ENTERED AT 12:39:37 ON 30 NOV 2004  
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'PROUSDDR' ENTERED AT 12:39:37 ON 30 NOV 2004  
COPYRIGHT (C) 2004 Prous Science

PROCESSING COMPLETED FOR L16

PROCESSING COMPLETED FOR L19

PROCESSING COMPLETED FOR L25

PROCESSING COMPLETED FOR L28

L39 16 DUP REM L16 L19 L25 L28 (8 DUPLICATES REMOVED)

ANSWERS '1-5' FROM FILE CAPLUS

ANSWERS '6-8' FROM FILE USPATFULL

ANSWERS '9-12' FROM FILE TOXCENTER

ANSWERS '13-14' FROM FILE IMSDRUGNEWS

ANSWER '15' FROM FILE IMSRESEARCH

ANSWER '16' FROM FILE PROUSDDR

=> d ibib ed abs hitstr 1-8; d iall 9-16

L39 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 2004:817412 CAPLUS

DOCUMENT NUMBER: 141:307511

TITLE: Antitumor spisulosine compounds

INVENTOR(S): Rinehart, Kenneth L.; Warwick, Robert A.; Avila, Jesus; Fregeau Gallagher, Nancy L.; Garcia Gravalos, Dolores; Faircloth, Glynn T.

PATENT ASSIGNEE(S): Board of Trustees of the University of Illinois, USA

SOURCE: U.S., 23 pp., Cont.-in-part of U.S. 6,107,520.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6800661	B1	20041005	US 1999-386724	19990831
US 6107520	A	20000822	US 1998-58456	19980410
US 2004147615	A1	20040729	US 2003-693174	20031023
PRIORITY APPLN. INFO.:			US 1997-43326P	P 19970415
			US 1997-43599P	P 19970415
			US 1998-58456	A2 19980410
			US 1999-386724	A1 19990831

ED Entered STN: 07 Oct 2004

AB Investigation of the activity of exts. of the clam *Spisula polynyma* has led to antitumor long-chain, straight-chain alkane or alkene compds. which have a 2-amino group and a 3-hydroxy group. Isolation and preparation of spisulosine compds. are described.


IT 117828-55-4 117828-59-8

RL: PAC (Pharmacological activity); BIOL (Biological study)  
(antitumor spisulosine compds.)

RN 117828-55-4 CAPLUS

CN 5,7-Tetradecadien-3-ol, 2-amino-, (2S,3S,5E,7E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 117828-59-8 CAPLUS

CN 5,7-Tetradecadien-3-ol, 2-amino-, (2S,3R,5E,7E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




IT 196497-48-0P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (antitumor spisulosine compds.)

RN 196497-48-0 CAPLUS

CN 3-Octadecanol, 2-amino-, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 247112-80-7 247112-81-8

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (antitumor spisulosine compds.)

RN 247112-80-7 CAPLUS


CN 3-Nonadecanol, 2-amino-, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247112-81-8 CAPLUS  
CN 3-Eicosanol, 2-amino-, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L39 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 3

ACCESSION NUMBER: 2003:446952 CAPLUS

DOCUMENT NUMBER: 140:22553

TITLE: Quantitative analysis of ES-285, an investigational marine anticancer drug, in human, mouse, rat, and dog plasma using coupled liquid chromatography and tandem mass spectrometry

AUTHOR(S): Stokvis, E.; Nan-Offeringa, L.; Rosing, H.; Lopez-Lazaro, L.; Acena, J. L.; Miranda, E.; Lyubimov, A.; Levine, B. S.; D'Aleo, C.; Schellens, J. H. M.; Beijnen, J. H.

CORPORATE SOURCE: Department of Pharmacy and Pharmacology, Slotervaart Hospital/The Netherlands Cancer Institute, Amsterdam, 1066 EC, Neth.

SOURCE: Journal of Mass Spectrometry (2003), 38(5), 548-554  
CODEN: JMSPFJ; ISSN: 1076-5174

PUBLISHER: John Wiley & Sons Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 11 Jun 2003

AB A method was developed for the quant. anal. of the novel anticancer agent ES-285 (spisulosine; free base) in human, mouse, rat, and dog plasma using high-performance liquid chromatog./electrospray ionization tandem mass spectrometry in order to support pre-clin. and clin. studies with the drug. Sample preparation was carried out by protein precipitation with acetonitrile, containing isotopically labeled (d3) ES-285 as internal standard Aliquots of 10 µL of the supernatant were injected directly on to an Inertsil ODS-3 column (50+2.0 mm i.d., 5 µm). Elution was carried out using methanol-10 mM ammonium formate (pH 4) in water (80:20, volume/volume) pumped at a flow-rate of 0.2 mL min<sup>-1</sup> with a run time of 8 min. Multiple reaction monitoring chromatograms obtained on an API365 triple-quadrupole mass spectrometer were used for quantification. The lower limit of quantitation (LLOQ) was 10 ng mL<sup>-1</sup> in human, mouse, rat, and dog plasma and the linear dynamic range extended to 500 ng mL<sup>-1</sup>. A full validation of the method was performed in human plasma, and partial validations were performed in mouse, rat and dog plasma. Accuracies and precisions were <20% at the LLOQ concentration and <15% for all other concns. in all matrixes. ES-285 was stable during all steps of the assay. Thus far this method has been used successfully to analyze over 500 samples in pre-clin. trials, and will be implemented in the planned clin. phase I studies.


IT 196497-48-0, ES-285

RL: ANT (Analyte); ANST (Analytical study)  
(quant. anal. of anticancer ES-285 in human and animal plasma by coupled liquid chromatog. and tandem mass spectrometry)

RN 196497-48-0 CAPLUS

CN 3-Octadecanol, 2-amino-, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L39 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 4  
ACCESSION NUMBER: 2001:904189 CAPLUS  
DOCUMENT NUMBER: 136:19976  
TITLE: Preparation of spisulosine derivatives for therapeutic use as antitumor agents.  
INVENTOR(S): Acena, Jose Luis; Adrio, Javier; Cuevas, Carmen; Gallego, Pilar; Manzanares, Ignacio; Munt, Simon; Rodriguez, Ignacio  
PATENT ASSIGNEE(S): Pharma Mar, S.A., Spain  
SOURCE: PCT Int. Appl., 167 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001094357	A1	20011213	WO 2001-GB2487	20010606
W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	
RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG	
CA 2410409	AA	20011213	CA 2001-2410409	20010606
EP 1287006	A1	20030305	EP 2001-936649	20010606
R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR	
BR 2001011505	A	20030624	BR 2001-11505	20010606
JP 2003535868	T2	20031202	JP 2002-501905	20010606
US 2004048834	A1	20040311	US 2003-297352	20030818
PRIORITY APPLN. INFO.:			GB 2000-13783	A 20000606
			GB 2001-2472	A 20010131
			GB 2001-4732	A 20010226
			WO 2001-GB2487	W 20010606

OTHER SOURCE(S): MARPAT 136:19976

ED Entered STN: 14 Dec 2001

AB Spisulosine derivs., such as X<sub>1</sub>X<sub>2</sub>X<sub>3</sub>C(CH<sub>2</sub>)<sub>n</sub>C(Y)CH(NR<sub>2</sub>R<sub>3</sub>)(CH<sub>2</sub>)<sub>m</sub>CZ<sub>1</sub>Z<sub>2</sub>Z<sub>3</sub>  
[X<sub>1</sub>-3, Z<sub>1</sub>-3 = H, OH, SH, CN, NO<sub>2</sub>, NH<sub>2</sub>, CO<sub>2</sub>H, CO<sub>2</sub>Me, alkoxy, alkylthio, alkylsulfonyl, alkylamino, acyl, carboxy, acylamino, halogen, etc.; Y = H, OH, NH<sub>2</sub>, :O, halogen, alkylamino, acyl, phosphoryl, phosphinyl, sulfo, etc.; R<sub>2</sub>, R<sub>3</sub> = H, alkyl, alkenyl, acyl, thioacyl, phosphinyl, sulfo, etc.; n = integer 0-25; m = integer 0-20], were prepared for pharmaceutical use as antitumor agents. Thus, (2R,3R)-Me(CH<sub>2</sub>)<sub>14</sub>CH(OH)CH(NH<sub>2</sub>)CH<sub>2</sub>F was prepared via

a multistep synthetic sequence starting from D-erythro-sphingosine. The prepared spisulosine derivs. were tested for cytotoxicity against a variety of cancer cell lines, such as bladder, breast, colon, etc.

IT 247067-50-1P 247112-80-7P 247112-81-8P

378753-61-8P 378753-91-4P 378754-86-0P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of sphingosine analogs for pharmaceutical use as antitumor agents.)

RN 247067-50-1 CAPLUS

CN 3-Octadecanol, 2-amino-, (2S,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 247112-80-7 CAPLUS

CN 3-Nonadecanol, 2-amino-, (2S,3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 247112-81-8 CAPLUS

CN 3-Eicosanol, 2-amino-, (2S,3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 378753-61-8 CAPLUS

CN 3-Heptadecanol, 2-amino-, (2S,3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 378753-91-4 CAPLUS  
CN 3-Heneicosanol, 2-amino-, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 378754-86-0 CAPLUS  
CN 3-Octadecanol, 2-amino-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 196497-48-0  
RL: PAC (Pharmacological activity); RCT (Reactant); THU (Therapeutic use);  
BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)  
(preparation of sphingosine analogs for pharmaceutical use as antitumor  
agents.)

RN 196497-48-0 CAPLUS  
CN 3-Octadecanol, 2-amino-, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 129825-28-1P 350478-04-5P 378753-41-4P  
378753-55-0P 378753-64-1P 378753-69-6P  
378753-73-2P 378753-80-1P 378753-86-7P  
378753-95-8P 378754-02-0P 378754-10-0P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(preparation of sphingosine analogs for pharmaceutical use as antitumor  
agents.)


RN 129825-28-1 CAPLUS  
CN 3-Tetradecanol, 2-amino-, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 350478-04-5 CAPLUS  
CN 3-Hexadecanol, 2-amino-, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 378753-41-4 CAPLUS  
CN 3-Pentadecanol, 2-amino-, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 378753-55-0 CAPLUS  
CN 3-Hexadecanol, 2-amino-, hydrochloride, (2S,3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 378753-64-1 CAPLUS  
CN 3-Heptadecanol, 2-amino-, hydrochloride, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 378753-69-6 CAPLUS  
CN 3-Octadecanol, 2-amino-, (2S,3R)-, (2R,3R)-2,3-dihydroxybutanedioate (2:1)  
(salt) (9CI) (CA INDEX NAME)

CM 1

CRN 196497-48-0  
CMF C18 H39 N O


Absolute stereochemistry.



CM 2


CRN 87-69-4  
CMF C4 H6 O6

Absolute stereochemistry.



RN 378753-73-2 CAPLUS  
CN 3-Octadecanol, 2-amino-, hydrochloride, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 378753-80-1 CAPLUS

CN 3-Nonadecanol, 2-amino-, hydrochloride, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 378753-86-7 CAPLUS

CN 3-Eicosanol, 2-amino-, hydrochloride, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 378753-95-8 CAPLUS

CN 3-Heneicosanol, 2-amino-, hydrochloride, (2S,3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 378754-02-0 CAPLUS  
CN 3-Docosanol, 2-amino-, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 378754-10-0 CAPLUS  
CN 3-Tricosanol, 2-amino-, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L39 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 6  
ACCESSION NUMBER: 2000:221294 CAPLUS  
DOCUMENT NUMBER: 133:99203  
TITLE: The marine compound spisulosine, an inhibitor of cell proliferation, promotes the disassembly of actin stress fibers  
AUTHOR(S): Cuadros, R.; Montejo de Garcini, E.; Wandosell, F.; Faircloth, G.; Fernandez-Sousa, J. M.; Avila, J.  
CORPORATE SOURCE: Centro de Biologia Molecular 'Severo Ochoa' (CSIC-UAM), Universidad Autonoma de Madrid, Madrid, 28049, Spain  
SOURCE: Cancer Letters (Shannon, Ireland) (2000), 152(1), 23-29  
CODEN: CALEDQ; ISSN: 0304-3835  
PUBLISHER: Elsevier Science Ireland Ltd.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
ED Entered STN: 06 Apr 2000  
AB Spisulosine is a novel antiproliferative (antitumoral) compound of marine origin. In this work the mol. target for this toxic agent has been

analyzed. In the presence of spisulosine, cultured cells change their morphol., first acquiring a fusiform morphol., and later becoming rounded without focal adhesions. Anal. of the cytoskeleton of treated cells indicate the absence of actin stress fibers.

IT 196497-48-0


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(spisulosine promotes disassembly of actin stress fibers)

RN 196497-48-0 CAPLUS

CN 3-Octadecanol, 2-amino-, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L39 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 7

ACCESSION NUMBER: 1999:672566 CAPLUS

DOCUMENT NUMBER: 131:295576

TITLE: Spisulosine compounds having antitumor activity

INVENTOR(S): Rinehart, Kenneth Lloyd; Fregeau, Nancy Louise; Warwick, Robert Arthur; Garcia Gravalos, Dolores; Avila, Jesus; Faircloth, Glynn Thomas

PATENT ASSIGNEE(S): The Board of Trustees of the University of Illinois, USA; Ruffles, Graham Keith

SOURCE: PCT Int. Appl., 73 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9952521	A1	19991021	WO 1999-GB1091	19990409
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6107520	A	20000822	US 1998-58456	19980410
CA 2328126	AA	19991021	CA 1999-2328126	19990409
AU 9934321	A1	19991101	AU 1999-34321	19990409
AU 763981	B2	20030807		
BR 9910120	A	20001226	BR 1999-10120	19990409
TR 200002955	T2	20010122	TR 2000-200002955	19990409
EP 1069894	A1	20010124	EP 1999-915898	19990409
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			

JP 2002511410	T2	20020416	JP 2000-543131	19990409
NZ 507349	A	20021220	NZ 1999-507349	19990409
RU 2225710	C2	20040320	RU 2000-128037	19990409
NO 2000005052	A	20001207	NO 2000-5052	20001006
BG 104935	A	20010731	BG 2000-104935	20001109
PRIORITY APPLN. INFO.:			US 1998-58456	A 19980410
			US 1997-43326P	P 19970415
			US 1997-43599P	P 19970415
			WO 1999-GB1091	W 19990409

ED Entered STN: 22 Oct 1999

AB Investigation of the activity of exts. of the clam *Spisula polynyma* has led to antitumor long-chain, straight-chain alkane or alkene compds. which have a 2-amino group and a 3-hydroxy group.


IT **196497-48-0P**, Spisulosine 285

RL: BAC (Biological activity or effector, except adverse); BOC (Biological occurrence); BSU (Biological study, unclassified); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); USES (Uses) (spisulosine compds. having antitumor activity)

RN 196497-48-0 CAPLUS

CN 3-Octadecanol, 2-amino-, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT **247112-80-7P**, Spisulosine 299 **247112-81-8P**, Spisulosine 313

RL: BAC (Biological activity or effector, except adverse); BOC (Biological occurrence); BSU (Biological study, unclassified); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); USES (Uses) (spisulosine compds. having antitumor activity)

RN 247112-80-7 CAPLUS

CN 3-Nonadecanol, 2-amino-, (2S,3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 247112-81-8 CAPLUS

CN 3-Eicosanol, 2-amino-, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 247067-50-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(spisulosine compds. having antitumor activity)

RN 247067-50-1 CAPLUS

CN 3-Octadecanol, 2-amino-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L39 ANSWER 6 OF 16 USPATFULL on STN

DUPLICATE 5

ACCESSION NUMBER: 2000:110024 USPATFULL

TITLE: Spisulosine compounds

INVENTOR(S): Rinehart, Kenneth L., Urbana, IL, United States

Fregeau, Nancy L., Wheeling, IL, United States

Warwick, Robert A., Urbana, IL, United States

PATENT ASSIGNEE(S): The Board of Trustees of the University of Illinois, Urbana, IL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6107520		20000822
APPLICATION INFO.:	US 1998-58456		19980410 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-43326P	19970415 (60)
	US 1997-43599P	19970415 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Lee, Howard C.	
ASSISTANT EXAMINER:	White, Everett	
LEGAL REPRESENTATIVE:	Linek, Ernest V. Banner & Witcoff, Ltd.	
NUMBER OF CLAIMS:	4	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)	
LINE COUNT:	1410	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to the isolation and bioactive characterization of compounds isolated from the clam *Spisula polynyma*. These compounds include three sphingoid-type bases, spisulosines 285,



299 and 313 (1-3), each of which shows unique cytotoxicity against L1210 murine lymphocytic leukemia cells. In addition, sphingosine (also referred to as 4-sphingenine or octadeca-4-sphingenine, 4) and two related compounds, nonadeca-4-sphingenine (a one carbon longer homolog, 5) and sphinga-4,10-diene (a dehydrosphingosine derivative, 6) were also obtained. These compounds also contribute to the cytotoxicity of the *Spisula polynyma* extracts, but did not cause the morphology changes observed with compounds 1-3.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT **196497-48-0P**, Spisulosine 285

(spisulosine compds. having antitumor activity)

RN 196497-48-0 USPATFULL

CN 3-Octadecanol, 2-amino-, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT **247112-80-7P**, Spisulosine 299 **247112-81-8P**, Spisulosine 313

(spisulosine compds. having antitumor activity)

RN 247112-80-7 USPATFULL

CN 3-Nonadecanol, 2-amino-, (2S,3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 247112-81-8 USPATFULL

CN 3-Eicosanol, 2-amino-, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT **247067-50-1P**

(spisulosine compds. having antitumor activity)

RN 247067-50-1 USPATFULL

CN 3-Octadecanol, 2-amino-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L39 ANSWER 7 OF 16 USPATFULL on STN

ACCESSION NUMBER: 2004:190841 USPATFULL

TITLE: Spisulosine compounds

INVENTOR(S): Rinehart, Kenneth L., Urbana, IL, UNITED STATES  
Warwick, Robert A., Urbana, IL, UNITED STATES  
Avila, Jesus, Madrid, SPAIN  
Fregeau Gallagher, Nancy L., Wheeling, IL, UNITED STATES  
Gravalos, Dolores Garcia, Madrid, SPAIN  
Faircloth, Glynn T., Cambridge, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004147615	A1	20040729
APPLICATION INFO.:	US 2003-693174	A1	20031023 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-386724, filed on 31 Aug 1999, PENDING Continuation-in-part of Ser. No. US 1998-58456, filed on 10 Apr 1998, GRANTED, Pat. No. US 6107520		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	MORGAN & FINNEGAN, L.L.P., 345 Park Avenue, New York, NY, 10154-0053		
NUMBER OF CLAIMS:	18		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	6 Drawing Page(s)		
LINE COUNT:	1700		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			
AB	Investigation of the activity of extracts of the clam Spisula polynyma has led to antitumour long-chain, straight-chain alkane or alkene compounds which have a 2-amino group and a 3-hydroxy group.		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 196497-48-0P, Spisulosine 285

(spisulosine compds. having antitumor activity)

RN 196497-48-0 USPATFULL

CN 3-Octadecanol, 2-amino-, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 247112-80-7P, Spisulosine 299 247112-81-8P, Spisulosine 313

(spisulosine compds. having antitumor activity)

RN 247112-80-7 USPATFULL

CN 3-Nonadecanol, 2-amino-, (2S,3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 247112-81-8 USPATFULL

CN 3-Eicosanol, 2-amino-, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 247067-50-1P

(spisulosine compds. having antitumor activity)

RN 247067-50-1 USPATFULL

CN 3-Octadecanol, 2-amino-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L39 ANSWER 8 OF 16 USPATFULL on STN

ACCESSION NUMBER: 2004:64315 USPATFULL

TITLE: Antitumoral compounds

INVENTOR(S): Acena, Jose Luis, Madrid, SPAIN  
Adrjo, Javier, Madrid, SPAIN  
Cuevas, Carmen, Madrid, SPAIN  
Gallego, Pilar, Madrid, SPAIN  
Manzanares, Ignacio, Madrid, SPAIN  
Munt, Simon, Madrid, SPAIN  
Rodriguez, Ignacio, Madrid, SPAIN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004048834	A1	20040311
APPLICATION INFO.:	US 2003-297352	A1	20030818 (10)
	WO 2001-GB2487		20010606

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2000-13783	20000606
	GB 2001-2472	20010131

DOCUMENT TYPE: GB 2001-4732 20010226  
UTILITY  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: FISH & RICHARDSON PC, 225 FRANKLIN ST, BOSTON, MA,  
02110  
NUMBER OF CLAIMS: 20  
EXEMPLARY CLAIM: 1  
LINE COUNT: 2906

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB New spisulosine derivatives of use in treating tumors are of the formula (I) wherein: each X is the same or different, and represents H, OH, OR', SH, SR', SOR', SO.sub.2R', NO.sub.2, NH.sub.2, NHR', N(R').sub.2, CN, halogen, C(.dbd.O)H, C(.dbd.O)CH.sub.3, CO.sub.2H, CO.sub.2CH.sub.3, substituted or unsubstituted C.sub.1-C.sub.18 alkyl, substituted or unsubstituted C.sub.2-C.sub.18 alkenyl, substituted or unsubstituted C.sub.2-C.sub.18 alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaromatic, or two groups X may together form .dbd.O; Y is NR.sub.1, OR.sub.1, PR.sub.1, SR.sub.1, or halogen, wherein the number of substituents R.sub.1 is selected to suit the valency and each R.sub.1 is independently selected of H, OH, C(.dbd.O)R', P(.dbd.O)R'R", substituted or unsubstituted C.sub.1-C.sub.18 alkyl, substituted or unsubstituted C.sub.2-C.sub.18 alkenyl, substituted or unsubstituted C.sub.2-C.sub.18 alkynyl, substituted or unsubstituted aryl, and wherein the dotted line indicates an optional double bond; each Z is the same different, and represents H, OH, OR', SH, SR', SOR', SO.sub.2R', NO.sub.2, NH.sub.2, NHR', N(R').sub.2, NHC(O)R', CN, halogen, C(.dbd.O)H, C(.dbd.O)CH.sub.3, CO.sub.2H, CO.sub.2CH.sub.3, substituted or unsubstituted C.sub.1-C.sub.18 alkyl, substituted or unsubstituted C.sub.2-C.sub.18 alkenyl, substituted or unsubstituted C.sub.2-C.sub.18 alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaromatic, or two groups Z may together form .dbd.O; z is 0 to 25; y is 0 to 20; R.sub.2 is H, C(.dbd.O)R', P(.dbd.O)R'R", S(.dbd.O)R'R", S(.dbd.O).sub.2R', substituted or unsubstituted C.sub.1-C.sub.18 alkyl, substituted or unsubstituted C.sub.2-C.sub.18 Alkenyl, substituted or unsubstituted C.sub.2-C.sub.18 alkynyl, substituted or unsubstituted aryl; R.sub.3 is H, C(.dbd.O)R', P(.dbd.O)R'R", S(.dbd.O)R'R", S(.dbd.O).sub.2R', substituted or unsubstituted C.sub.1-C.sub.18 alkyl, substituted or unsubstituted C.sub.2-C.sub.18 alkenyl, substituted or unsubstituted C.sub.2-C.sub.18 alkynyl, substituted or unsubstituted aryl; each of the R', R" groups is independently selected from the group consisting of H, OH, NO.sub.2, NH.sub.2, SH, CN, halogen, .dbd.O, C(.dbd.O)H, C(.dbd.O)CH.sub.3, CO.sub.2H, CO.sub.2CH.sub.3, substituted or unsubstituted C.sub.1-C.sub.18 alkyl, substituted or unsubstituted C.sub.1-C.sub.18 alkoxy, substituted or unsubstituted C.sub.2-C.sub.18 alkenyl, substituted or unsubstituted C.sub.2-C.sub.18 alkynyl, substituted or unsubstituted aryl; there may be one or more unsaturations in the hydrocarbon backbone defined by the chain (II) and salts thereof; with the exception of a C.sub.16-C.sub.24 2-amino-3-hydroxyalkane or a C.sub.16-C.sub.24 2-amino-3-hydroxyalkene.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 247067-50-1P 247112-80-7P 247112-81-8P


378753-61-8P 378753-91-4P 378754-86-0P

(preparation of sphingosine analogs for pharmaceutical use as antitumor agents.)

RN 247067-50-1 USPATFULL


CN 3-Octadecanol, 2-amino-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 247112-80-7 USPATFULL  
CN 3-Nonadecanol, 2-amino-, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 247112-81-8 USPATFULL  
CN 3-Eicosanol, 2-amino-, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 378753-61-8 USPATFULL  
CN 3-Heptadecanol, 2-amino-, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 378753-91-4 USPATFULL  
CN 3-Heneicosanol, 2-amino-, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 378754-86-0 USPATFULL  
CN 3-Octadecanol, 2-amino-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 196497-48-0

(preparation of sphingosine analogs for pharmaceutical use as antitumor agents.)

RN 196497-48-0 USPATFULL

CN 3-Octadecanol, 2-amino-, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 129825-28-1P 350478-04-5P 378753-41-4P

378753-55-0P 378753-64-1P 378753-69-6P

378753-73-2P 378753-80-1P 378753-86-7P


378753-95-8P 378754-02-0P 378754-10-0P

(preparation of sphingosine analogs for pharmaceutical use as antitumor agents.)

RN 129825-28-1 USPATFULL

CN 3-Tetradecanol, 2-amino-, (2S,3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 350478-04-5 USPATFULL

CN 3-Hexadecanol, 2-amino-, (2S,3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 378753-41-4 USPATFULL

CN 3-Pentadecanol, 2-amino-, (2S,3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 378753-55-0 USPATFULL

CN 3-Hexadecanol, 2-amino-, hydrochloride, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 378753-64-1 USPATFULL

CN 3-Heptadecanol, 2-amino-, hydrochloride, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 378753-69-6 USPATFULL


CN 3-Octadecanol, 2-amino-, (2S,3R)-, (2R,3R)-2,3-dihydroxybutanedioate (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 196497-48-0

CMF C18 H39 N O


Absolute stereochemistry.



CM 2


CRN 87-69-4  
CMF C4 H6 O6  
CDES 1:R2:R\*,R\*

Absolute stereochemistry.



RN 378753-73-2 USPATFULL  
CN 3-Octadecanol, 2-amino-, hydrochloride, (2S,3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 378753-80-1 USPATFULL  
CN 3-Nonadecanol, 2-amino-, hydrochloride, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 378753-86-7 USPATFULL  
CN 3-Eicosanol, 2-amino-, hydrochloride, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






● HCl

RN 378753-95-8 USPATFULL  
CN 3-Heneicosanol, 2-amino-, hydrochloride, (2S,3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 378754-02-0 USPATFULL  
CN 3-Docosanol, 2-amino-, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 378754-10-0 USPATFULL  
CN 3-Tricosanol, 2-amino-, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L39 ANSWER 9 OF 16 TOXCENTER COPYRIGHT 2004 ACS on STN DUPLICATE 2  
ACCESSION NUMBER: 2004:183101 TOXCENTER

COPYRIGHT: Copyright 2004 ACS  
DOCUMENT NUMBER: CA14114218241F  
TITLE: A more sensitive MS detector does not obviously lead to a more sensitive assay: Experiences with ES-285  
AUTHOR(S): Stokvis, Ellen; Rosing, Hilde; Lopez-Lazaro, Luis; Schellens, Jan H. M.; Beijnen, Jos H.  
CORPORATE SOURCE: Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Slotervaart Hospital, Amsterdam, 1066 EC, Neth..  
SOURCE: Biomedical Chromatography, (2004) Vol. 18, No. 6, pp. 403-407.  
CODEN: BICHE2. ISSN: 0269-3879.  
COUNTRY: NETHERLANDS  
DOCUMENT TYPE: Journal  
FILE SEGMENT: CAPLUS  
OTHER SOURCE: CAPLUS 2004:654293  
LANGUAGE: English  
ENTRY DATE: Entered STN: 20040817  
Last Updated on STN: 20040928

## ABSTRACT:

In this paper the transfer of an existing method for the quant. determination of the \*\*\*anticancer\*\*\* agent ES-285 in human plasma using liquid chromatog. tandem mass spectrometry on an API 365 to an API 3000 mass spectrometer is described. The transfer appeared not to be straightforward. Problems arose resulting from carry-over and interferences. In addition, due to the expansion of the calibration range, data ought to be weighted with a different factor to increase the accuracy of the lower concns. After finding appropriate solns. for these problems, the lower limit of quantitation could be lowered from 10 to 1 ng/mL for ES-285 in human plasma. The usefulness and necessity of the modified assay was demonstrated by anal. of plasma samples from a patient receiving a low dosage of the drug.

CLASSIFICATION CODE: 1-1

SUPPLEMENTARY TERMS: Miscellaneous Descriptors  
ES285 API365 API3000 mass spectrometer sensitivity

REGISTRY NUMBER: 196497-48-0 (ES-285)

L39 ANSWER 10 OF 16 TOXCENTER COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004:60956 TOXCENTER

COPYRIGHT: Copyright 2004 ACS

DOCUMENT NUMBER: CA14119320221M

TITLE: Development and validation of a liquid chromatography-ultraviolet absorbance detection assay using derivatization for the novel marine anticancer agent ES-285·HCl [(2S,3R)-2-amino-3-octadecanol hydrochloride] and its pharmaceutical dosage form. [Erratum to document cited in CA140:099740]

AUTHOR(S): den Brok, Monique W. J.; Nuijen, Bastiaan; Miranda, Elena; Floriano, Pablo; Munt, Simon; Manzanares, Ignacio; Beijnen, Jos H.

CORPORATE SOURCE: The Netherlands Cancer Institute, Department of Pharmacy and Pharmacology, Slotervaart Hospital, Amsterdam, 1066 EC, Neth..

SOURCE: Journal of Chromatography, A, (2004) Vol. 1033, No. 1, pp. 191.

CODEN: JCRAEY. ISSN: 0021-9673.

COUNTRY: NETHERLANDS

DOCUMENT TYPE: Journal

FILE SEGMENT: CAPLUS

OTHER SOURCE: CAPLUS 2004:191774

LANGUAGE: English

ENTRY DATE: Entered STN: 20040316

*Registry records printed  
beginning on pg. 34*

Last Updated on STN: 20041102

ABSTRACT:

On page 257, column 2, line 4 from the bottom, "response range of 10.19-1.16 min" should read "response range of 1.19-11.16 min".

CLASSIFICATION CODE: 64-3

SUPPLEMENTARY TERMS: Miscellaneous Descriptors

erratum ES285 detn liq chromatog phenylisothiocyanate

REGISTRY NUMBER: **196497-48-0** (ES-285)

378755-42-1 (Thiourea, N-[(1S,2R)-2-hydroxy-1-methylheptadecyl]-N'-phenyl-)

103-72-0 (Phenylisothiocyanate)

7585-39-9Q ( $\beta$ -Cyclodextrin, 2-hydroxypropyl derivs.)

REGISTRY NUMBER: **247112-80-7; 247112-81-8;**

**350478-04-5; 378753-61-8;** 378754-16-6;

378754-25-7; 378754-34-8; 643033-63-0; 643033-64-1;

643033-65-2; 643033-66-3; 643033-68-5; 643033-69-6;

643033-70-9; 643033-71-0; 643033-72-1; 643033-73-2;

643033-74-3; 643033-76-5; 643033-77-6; 643033-78-7;

643033-79-8; **378753-73-2**

L39 ANSWER 11 OF 16 TOXCENTER COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:266016 TOXCENTER

COPYRIGHT: Copyright 2004 ACS

DOCUMENT NUMBER: CA14007099740K

TITLE: Development and validation of a liquid chromatography-ultraviolet absorbance detection assay using derivatization for the novel marine **anticancer** agent ES-285·HCl

[(2S,3R)-2-amino-3-octadecanol hydrochloride] and its pharmaceutical dosage form

AUTHOR(S): den Brok, Monique W. J.; Nuijen, Bastiaan; Miranda, Elena; Floriano, Pablo; Munt, Simon; Manzanares, Ignacio; Beijnen, Jos H.

CORPORATE SOURCE: The Netherlands Cancer Institute, Department of Pharmacy & Pharmacology, Slotervaart Hospital, Amsterdam, 1066 EC, Neth..

SOURCE: Journal of Chromatography, A, (2003) Vol. 1020, No. 2, pp. 251-258.

CODEN: JCRAEY. ISSN: 0021-9673.

COUNTRY: NETHERLANDS

DOCUMENT TYPE: Journal

FILE SEGMENT: CAPLUS

OTHER SOURCE: CAPLUS 2003:846886

LANGUAGE: English

ENTRY DATE: Entered STN: 20031104

Last Updated on STN: 20040210

ABSTRACT:

ES-285·HCl [(2S,3R)-2-amino-3-octadecanol hydrochloride] is a novel investigational **anticancer** agent, which has shown in vitro and in vivo cytotoxic activity against various **tumor** cell lines with selectivity for certain solid **tumors**. The pharmaceutical development of ES-285·HCl warranted the availability of an assay for the quantification and purity determination of ES-285·HCl active pharmaceutical ingredient (API) and its pharmaceutical dosage form. A liquid chromatog. method (LC) comprising of derivatization of ES-285·HCl with phenylisothiocyanate and UV-detection was developed. The method was found to be linear, precise and accurate. The assay also proved selectivity as determined by analyzing ES-285·HCl in combination with 15 analogs and in combination with hydroxypropyl- $\beta$ -cyclodextrin, the excipient used in the lyophilized pharmaceutical dosage form. Stress testing showed that the degradation products were separated from the parent compound, confirming its stability indicating capacity. The method was found robust as determined with design of expts. (DoE),

which made it possible to predict system suitability responses in worst case exptl. conditions and to define criteria for system suitability testing.

CLASSIFICATION CODE: 64-3

SUPPLEMENTARY TERMS: Miscellaneous Descriptors

ES285 detn liq chromatog phenylisothiocyanate

REGISTRY NUMBER: **196497-48-0** (ES-285)

103-72-0 (Phenylisothiocyanate)

7585-39-9Q ( $\beta$ -Cyclodextrin, 2-hydroxypropyl derivs.)

REGISTRY NUMBER: **247112-80-7; 247112-81-8;**

**350478-04-5; 378753-61-8;** 378754-16-6;

378754-25-7; 378754-34-8; 643033-63-0; 643033-64-1;

643033-65-2; 643033-66-3; 643033-68-5; 643033-69-6;

643033-70-9; 643033-71-0; 643033-72-1; 643033-73-2;

643033-74-3; 643033-76-5; 643033-77-6; 643033-78-7;

643033-79-8; **378753-73-2;** 378755-42-1

L39 ANSWER 12 OF 16 TOXCENTER COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:137236 TOXCENTER

COPYRIGHT: Copyright 2004 ACS

DOCUMENT NUMBER: CA13925374146T

TITLE: Phenylisothiocyanate and dansyl chloride precolumn derivatizations for the high-performance liquid chromatography analysis of the **antitumoral** agent ES-285 in dog plasma

AUTHOR(S): Maraschiello, C.; Miranda, E.; Millan, E.; Floriano, P.; Vilageliu, J.

CORPORATE SOURCE: S.A.L., Centro de Investigacion y Desarrollo Aplicado, Pharmacokinetics and Analytical Chemistry Department, Barcelona, 08130, Spain.

SOURCE: Journal of Chromatography, B: Analytical Technologies in the Biomedical and Life Sciences, (2003) Vol. 791, No. 1-2, pp. 1-11.

CODEN: JCBAAI. ISSN: 1570-0232.

COUNTRY: SPAIN

DOCUMENT TYPE: Journal

FILE SEGMENT: CAPLUS

OTHER SOURCE: CAPLUS 2003:427778

LANGUAGE: English

ENTRY DATE: Entered STN: 20030610

Last Updated on STN: 20031216

#### ABSTRACT:

Chromophore and fluorophore addition reactions involving phenylisothiocyanate (PITC) and dansyl chloride (DC) were optimized to adapt two high-performance liquid chromatog. (HPLC) procedures designed for the accurate determination of the novel **\*\*\*antitumoral\*\*\*** agent ES-285 in Beagle dog plasma. ES-285 was reacted with PITC at 60 for 15 min in the presence of triethylamine. The dansyl derivative was obtained by reaction of ES-285 with dansyl chloride in a basic medium at 80 for 20 min. Both reactions also worked for ES-299, a compound structurally related to ES-285 which was used as internal standard. The treatment of ES-285 and ES-299 spiked plasma samples with a basic phosphate buffer and MeOH permitted the extraction of the drug from the matrix. The purification of the analytes was carried out by solid-phase extraction followed by precolumn derivatization with PITC and DC. The phenylisothiocyanate adducts were analyzed by isocratic HPLC with UV detection at 254 nm. The ES-285 and ES-299 derivs. were eluted from a C18 column at .apprx.6.9 and .apprx.8.1 min, resp. The eluent ACN-water (95:5, volume/volume) was delivered to the column at a flow-rate of 1 mL/min and the anal. was completed in 15 min. The dansyl derivs. were analyzed by a two-HPLC column system with fluorescence detection and gradient elution. The column temperature was maintained at 40. The anal. lasted 55 min with the elution of ES-285 and ES-299 derivs. at .apprx.35.2 and .apprx.37.9 min, resp. The PITC- and DC-based procedures were characterized by limits of quantification of 20 and 15 ng/mL, resp. Both procedures were validated according to the ICH and FDA

guidelines. They were selective for ES-285 and provided accurate, precise and reproducible results. ES-299 was shown to be a suitable internal standard. The HPLC procedure involving derivatization with DC was more sensitive and permitted to process plasma sample vols. as low as 100 µl. The PITC-based procedure characterized by a quite similar LOQ permitted a higher throughput but implied the processing of a 500-µl plasma volume.

CLASSIFICATION CODE: 1-1

SUPPLEMENTARY TERMS: Miscellaneous Descriptors  
blood ES299 detn HPLC phenylisothiocyanate dansyl chloride  
derivatization

REGISTRY NUMBER: **196497-48-0** (ES 285)  
103-72-0 (Phenylisothiocyanate)  
605-65-2 (Dansyl chloride)

L39 ANSWER 13 OF 16 IMSDRUGNEWS COPYRIGHT 2004 IMSWORLD on STN

ACCESSION NUMBER: 2003:2779 IMSDRUGNEWS  
TITLE: spisulosine PharmaMar phase change I, Europe (cancer)  
SOURCE: R&D Focus Drug News (30 Jun 2003).  
WORD COUNT: 60  
TEXT:

PharmaMar has commenced patient enrollment in a phase I trial of ES 285, a naturally occurring sphingosine-like compound isolated from the edible Arctic clam *Mactromeris polynyma*. The European study involves administration of the agent to patients with advanced malignant solid tumors, for whom no other treatment option is available. Different dosing regimens and schedules of the agent will be investigated.

CHEMICAL NAME: spisulosine; ES 285  
CAS REGISTRY NUMBER: **196497-48-0**  
CLASSIFICATION: L1X9 All Other Antineoplastics  
COMPANY NAME: PharmaMar  
DEVELOPMENT STATUS: Phase I. Europe  
STATUS: new phase

L39 ANSWER 14 OF 16 IMSDRUGNEWS COPYRIGHT 2004 IMSWORLD on STN

ACCESSION NUMBER: 2000:3800 IMSDRUGNEWS  
TITLE: spisulosine PharmaMar preclinical data  
SOURCE: R&D Focus Drug News (20 Nov 2000).  
WORD COUNT: 139  
TEXT:

Phase I trials are planned by PharmaMar of spisulosine (ES 285), a potential cancer therapy isolated from the North Atlantic clam, *Spisula polynyma*, it was reported at the 11th NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy, 7-10 November 2000, in Amsterdam, the Netherlands. The compound is reported to promote the disassembly of actin stress fibers by inhibiting the activity of the GTP-binding protein, Rho. Data reported at the conference demonstrated that the agent is active in vitro against a range of human solid tumors, including colon, gastric, pancreas, pharyngeal and renal cancers, with IC50 values in the nanomolar range. In mice, the agent is active against prostate tumors. In vitro cytotoxicity studies in normal cells show some potential for liver and myelogenous stem cell toxicity and in vivo, some hepatic toxicity is seen at the maximum tolerated dose.


CHEMICAL NAME: spisulosine; ES 285  
CAS REGISTRY NUMBER: **196497-48-0**  
CLASSIFICATION: L1X9 All Other Antineoplastics

COMPANY NAME: PharmaMar  
DEVELOPMENT STATUS: preclinical data.  
STATUS: new drug

L39 ANSWER 15 OF 16 IMSRESEARCH COPYRIGHT 2004 IMSWORLD on STN

ACCESSION NUMBER: 2000:1065 IMSRESEARCH  
SOURCE: R&D Focus, (30 Jun 2003)  
GENERIC NAME: spisulosine  
LABORATORY NAME: ES 285  
CHEMICAL NAME: (2S,3R)-2-amino-3-octadecanol  
CAS REGISTRY NO.: 196497-48-0  
STRUCTURE:

Absolute stereochemistry.



DERIVATIVE(S): 196497-48-0spisulosine 285  
CLASSIFICATION: L1X9 All Other Antineoplastics  
INDICATION: cancer; solid tumor  
HIGHEST DEV. PHASE: Phase I (30)  
LATEST INFORMATION: PharmaMar has commenced patient enrollment in a phase I trial of ES 285, a naturally occurring sphingosine-like compound isolated from the edible Arctic clam Mactromeris polynyma. The European study involves administration of the agent to patients with advanced malignant solid tumors, for whom no other treatment option is available. Different dosing regimens and schedules of the agent will be investigated.

CURRENT DEVELOPMENT STATUS:

Type	Status	Stage	Region	Indication
Highest Phase	Phase I	30		
Phase	Phase I		Europe	solid tumor

COMPANY INFORMATION:

Type	Company	Nationality
Originator	PharmaMar	Spain
Assignee	Illinois University : Ruffles, G K	

PATENT SUMMARY:

Composition: WO 99/52521 1999, priority US 58456 1998, designating 99 states.  
One equivalent identified.

COMMERCIAL SUMMARY:

Commercial overview. PharmaMar is developing spisulosine, a naturally occurring

sphingosine-like compound isolated from the North Atlantic clam *Spisula* (*Mactromeris*) *polynyma*, as a potential anticancer agent (PharmaMar, NOV 2000). The company has initiated a phase I trial in patients with advanced malignant solid tumors, for whom no other treatment option is available. The European study will investigate different dosing regimens and schedules of the agent (PharmaMar, JUN 2003).

#### SCIENTIFIC SUMMARY:


Scientific overview. Spisulosine promotes the disassembly of actin stress fibers by inhibiting the activity of Rho. In vitro the agent was shown to be active against a range of human solid tumors, including colon, gastric, pancreas, pharyngeal and renal cancers, with IC50s in the nanomolar range. In mice the agent was shown to be active against prostate tumors. In vitro cytotoxicity studies in normal cells showed some potential for liver and myelogenous stem cell toxicity and in vivo some hepatic toxicity was seen at the maximum tolerated dose (11th NCI-EORTC-AACR, Abs 220, NOV 2000).

#### DEVELOPMENT HISTORY:

JUN 2003 Phase I, Europe (advanced solid tumors).  
NOV 2000 Preclinical, Spain.  
APR 1998 Priority composition patent application filed, USA.

L39 ANSWER 16 OF 16 PROUSDDR COPYRIGHT 2004 PROUS SCIENCE on STN  
ACCESSION NUMBER: 2001:76 PROUSDDR  
DOCUMENT NUMBER: 282749  
CHEMICAL NAME: 2(S)-Aminooctadecan-3(R)-ol  
DRUG NAME: ES-285  
GENERIC NAME: Spisulosine  
Spisulosine 285  
CAS REGISTRY NUMBER: **196497-48-0**  
MOLECULAR FORMULA: C18 H39 N O  
STATUS: Actively Investigated  
HIGHEST DEV. PHASE: PHASE I  
ORIGINATOR: PharmaMar  
University of Illinois  
CLASSIFICATION CODE: Gastric Cancer Therapy; Liver Cancer Therapy; Prostate Cancer Therapy; Renal Cancer Therapy  
ACTION MECHANISM: Inhibitors of Signal Transduction Pathways  
OTHER SOURCE: SYNTHLINE 2001000889  
ENTRY DATE: Entered STN: 9 May 2004  
Last Updated on STN: 2 Nov 2004

#### STRUCTURE:



#### PROUS REFERENCES:

RefID: 602551 (Text Available)  
Drug Data Report, Vol. 23, No. 2, pp 199, 2001

#### REFERENCE TEXT:

RefID: 602551  
ACTION - Antineoplastic agent, a sphingosine-like substance isolated from the clam *Spisula polynyma*, with selectivity for certain solid tumors including colon, gastric, pancreatic, pharyngeal and renal tumor cells, giving IC50 values in the nanomolar range, and particularly good activity against hepatoma SK-HEP-1

cells (IC50 = 0.562 pM); it showed generally lower activity against leukemias and lymphomas, and it was cytotoxic to normal cells only in the micromolar range. The cytotoxic activity of compound appeared to be mediated by inhibition of the Rho GTP-binding protein. Selected for clinical trials.

## PATENT REFERENCES:

TITLE: Spisulosine cpds. having antitumour activity  
INVENTOR(S): Rinehart, K.L.; Faircloth, G.T.; Garcia Gravalos, D.; Fregeau, N.L.; Warwick, R.A.; Avila, J.  
PATENT ASSIGNEE(S): University of Illinois  
PATENT INFORMATION: WO 9952521 19991021  
PRIORITY INFORMATION: US 1998-58456 19980410

TITLE: Antitumoral cpds.  
INVENTOR(S): Rodriguez, I.; Manzanares, I.; Gallego, P.; Acena, J.L.; Adrio, J.; Cuevas, C.; Munt, S.  
PATENT ASSIGNEE(S): PharmaMar  
PATENT INFORMATION: EP 1287006 20030305  
JP 2003535868 20031202  
US 2004048834 20040311  
WO 2001094357 20011213  
PRIORITY INFORMATION: GB 2000-13783 20000606  
GB 2001-2472 20010131  
GB 2001-4732 20010226

## REFERENCES:

- (1) RefID: 556795, Congress Literature  
"ES-285, a marine natural product with activity against solid tumors"  
Jimeno, J.M.; et al., AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther, Nov 16 1999-Nov 19 1999, Washington DC, (Abst 314)
- (2) RefID: 597253, Periodic Publication  
"The effects of spisulosine (es-285), a marine natural product on the morphology and survival of tumor cells"  
Cuadros, R.; et al., Clin Cancer Res, Vol. 6, No. Suppl., (Abst 220), 2000
- (3) RefID: 597403, Periodic Publication  
"The marine compound spisulosine, an inhibitor of cell proliferation, promotes the disassembly of actin stress fibers"  
Cuadros, R.; et al., Cancer Lett, Vol. 152, No. 1, pp 23, 2000
- (4) RefID: 602564, Periodic Publication  
"Pharmaceutical development of anticancer agents derived from marine sources"  
Nuijen, B.; et al., Anti-Cancer Drugs, Vol. 11, No. 10, pp 793, 2000
- (5) RefID: 612036, Periodic Publication  
"In vitro anti-proliferative effect on sarcoma cells by ET-743 and other marine chemotherapeutics"  
Shao, L.; Weissbach, L.; Faircloth, G.T.; Chabner, B.A.; Hornicek, F.J., Proc Am Assoc Cancer Res, Vol. 42, (Abst 1087), 2001
- (6) RefID: 614309, Periodic Publication  
"Novel marine derived anticancer agents ET-743, aplidine, spisulosine (ES-285) and kahalalide F are not transported by the breast cancer resistance protein"  
Maliepaard, M.; et al., Proc Am Assoc Cancer Res, Vol. 42, (Abst 4352), 2001



- (7) RefID: 679693, Periodic Publication  
"A clinical armamentarium of marine-derived anti-cancer compounds"  
Jimeno, J.M., Anti-Cancer Drugs, Vol. 13, No. Suppl. 1, pp S15, 2002
- (8) RefID: 750197, Periodic Publication  
"Phenylisothiocyanate and dansyl chloride precolumn derivatizations for the high-performance liquid chromatography analysis of the antitumoral agent ES-285 in dog plasma"  
Maraschiello, C.; et al., J Chromatogr B Anal Technol Biomed Life Sci, Vol. 791, No. 1-2, pp 1, 2003
- (9) RefID: 756898, Periodic Publication  
"ES-285, a novel antitumoral compound, interacts with EDG receptors"  
Salcedo, M.; Cuevas, C.; Sanchez-Puelles, J.M.; Otero, G.; Sousa, J.M.F.; Avila, J.; Wandosell, F., Proc Am Assoc Cancer Res, Vol. 44, No. 2nd ed, (Abst 3649), 2003
- (10) RefID: 777327, Congress Literature  
"Characterization of the mechanism of action of ES-285, a novel antitumor drug from Mactromeris poynyma"  
Alvarez-Miranda, M.; Rodriguez-Gonzalez, A.; Otero, G.; Lacal, J.C., AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther, Nov 17 2003-Nov 21 2003, Boston, (Abst C17)
- (11) RefID: 777331, Congress Literature  
"The marine antitumor compound ES 285 activates EGD receptors"  
Salcedo, M.; Cuevas, C.; Otero, G.; Sanchez-Puelles, J.M.; Fernandez-Sousa, J.M.; Avila, J.; Wandosell, F., AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther, Nov 17 2003-Nov 21 2003, Boston, (Abst C24)
- (12) RefID: 779856, Periodic Publication  
"Development and validation of a liquid chromatography-ultraviolet absorbance detection assay using derivatisation for the novel marine anticancer agent ES-285.HCl ((2S,3R)-2-amino-3-octadecanol hydrochloride) and its pharmaceutical dosage form"  
den Brok, M.W.J.; et al., J Chromatogr, Vol. 1020, No. 2, pp 251, 2003
- (13) RefID: 804757, Company Communication  
"PharmaMar reports 2003 year-end R&D highlights"  
PharmaMar Press Release, January 28, 2004
- (14) RefID: 817818, Periodic Publication  
"Development and validation of a liquid chromatography-ultraviolet absorbance detection assay using derivatisation for the novel marine anticancer agent ES-285.HCl ((2S,3R)-2-amino-3-octadecanol hydrochloride) and its pharmaceutical dosage form. (Erratum)"  
den Brok, M.W.J.; et al., J Chromatogr, Vol. 1033, No. 1, pp 191, 2004
- (15) RefID: 847116, Periodic Publication  
"A more sensitive NIS detector does not obviously lead to a more sensitive assay: Experiences with ES-285"  
Stokvis, E.; et al., BMC - Biomed Chromatogr, Vol. 18, No. 6, pp 403, 2004

START LOCAL KERMIT RECEIVE PROCESS

BINARY DATA HAVE BEEN DOWNLOADED TO MULTIPLES FILES 'IMAGENnn.TIF'

=> fil reg

FILE 'REGISTRY' ENTERED AT 12:41:53 ON 30 NOV 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 28 NOV 2004 HIGHEST RN 790189-55-8  
DICTIONARY FILE UPDATES: 28 NOV 2004 HIGHEST RN 790189-55-8

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more  
information enter HELP PROP at an arrow prompt in the file or refer  
to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> s 196497-48-0 or 247112-80-7 or 247112-81-8 or 350478-04-5 or 378753-61-8 or  
378753-73-2


1 196497-48-0  
(196497-48-0/RN)  
1 247112-80-7  
(247112-80-7/RN)  
1 247112-81-8  
(247112-81-8/RN)  
1 350478-04-5  
(350478-04-5/RN)  
1 378753-61-8  
(378753-61-8/RN)  
1 378753-73-2  
(378753-73-2/RN)

L40 6 196497-48-0 OR 247112-80-7 OR 247112-81-8 OR 350478-04-5 OR  
378753-61-8 OR 378753-73-2

=> d ide 1-6

L40 ANSWER 1 OF 6 REGISTRY COPYRIGHT 2004 ACS on STN  
RN **378753-73-2** REGISTRY  
CN 3-Octadecanol, 2-amino-, hydrochloride, (2S,3R)- (9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF C18 H39 N O . Cl H  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL  
DT.CA Caplus document type: Journal; Patent  
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES  
(Uses)  
RL.NP Roles from non-patents: ANST (Analytical study)  
CRN (196497-48-0)

Absolute stereochemistry.




● HCl

3 REFERENCES IN FILE CA (1907 TO DATE)  
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L40 ANSWER 2 OF 6 REGISTRY COPYRIGHT 2004 ACS on STN  
RN **378753-61-8** REGISTRY  
CN 3-Heptadecanol, 2-amino-, (2S,3R)- (9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF C17 H37 N O  
CI COM  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL  
DT.CA Caplus document type: Journal; Patent  
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
RL.NP Roles from non-patents: ANST (Analytical study)

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

3 REFERENCES IN FILE CA (1907 TO DATE)  
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L40 ANSWER 3 OF 6 REGISTRY COPYRIGHT 2004 ACS on STN  
RN **350478-04-5** REGISTRY  
CN 3-Hexadecanol, 2-amino-, (2S,3R)- (9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF C16 H35 N O  
CI COM  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL  
DT.CA Caplus document type: Journal; Patent  
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)  
RL.NP Roles from non-patents: ANST (Analytical study); PREP (Preparation); RACT (Reactant or reagent)

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

4 REFERENCES IN FILE CA (1907 TO DATE)

4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L40 ANSWER 4 OF 6 REGISTRY COPYRIGHT 2004 ACS on STN

RN **247112-81-8** REGISTRY

CN 3-Eicosanol, 2-amino-, (2S,3R)- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN Spisulosine 313

FS STEREOSEARCH

MF C20 H43 N O

CI COM

SR CA


LC STN Files: BIOSIS, CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA Caplus document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

RL.NP Roles from non-patents: ANST (Analytical study)

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

5 REFERENCES IN FILE CA (1907 TO DATE)

5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L40 ANSWER 5 OF 6 REGISTRY COPYRIGHT 2004 ACS on STN

RN **247112-80-7** REGISTRY

CN 3-Nonadecanol, 2-amino-, (2S,3R)- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN Spisulosine 299

FS STEREOSEARCH

MF C19 H41 N O

CI COM

SR CA


LC STN Files: BIOSIS, CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA Caplus document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

RL.NP Roles from non-patents: ANST (Analytical study)

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

5 REFERENCES IN FILE CA (1907 TO DATE)

5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L40 ANSWER 6 OF 6 REGISTRY COPYRIGHT 2004 ACS on STN

RN **196497-48-0** REGISTRY

CN 3-Octadecanol, 2-amino-, (2S,3R)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 3-Octadecanol, 2-amino-, [R-(R\*,S\*)]-

OTHER NAMES:

CN ES 285

CN Spisulosine 285

FS STEREOSEARCH

MF C18 H39 N O

CI COM

SR CA


LC STN Files: ANABSTR, BIOSIS, CA, CAPLUS, IMSDRUGNEWS, IMSRESEARCH, PROUSDDR, SYNTHLINE, TOXCENTER, USPATFULL

DT.CA Caplus document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); PROC (Process); USES (Uses)

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10 REFERENCES IN FILE CA (1907 TO DATE)

10 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> fil capl; d que nos l18; s l18 not l16  
FILE 'CAPLUS' ENTERED AT 12:42:19 ON 30 NOV 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 30 Nov 2004 VOL 141 ISS 23  
FILE LAST UPDATED: 28 Nov 2004 (20041128/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

*compd*  
+  
*Rho protein*

L1 STR  
L3 SCR 1830 AND 963 AND 1834  
L11 53 SEA FILE=REGISTRY SSS FUL L1 AND L3  
L13 31 SEA FILE=CAPLUS ABB=ON L11  
L17 3818 SEA FILE=CAPLUS ABB=ON (RHO(A)PROTEIN#)/BI  
L18 2 SEA FILE=CAPLUS ABB=ON L13 AND L17

L41 0 L18 NOT L16

*previously printed*

=> fil biosis toxcenter anabst; d que nos l27  
FILE 'BIOSIS' ENTERED AT 12:42:34 ON 30 NOV 2004  
Copyright (c) 2004 The Thomson Corporation.

FILE 'TOXCENTER' ENTERED AT 12:42:34 ON 30 NOV 2004  
COPYRIGHT (C) 2004 ACS

FILE 'ANABSTR' ENTERED AT 12:42:34 ON 30 NOV 2004  
COPYRIGHT (c) 2004 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

L1 STR  
L3 SCR 1830 AND 963 AND 1834  
L11 53 SEA FILE=REGISTRY SSS FUL L1 AND L3  
L20 17 SEA L11  
L26 17502 SEA RHO  
L27 0 SEA L26 AND L20

*previously printed*

=> fil reg; d stat que l36  
FILE 'REGISTRY' ENTERED AT 12:42:58 ON 30 NOV 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 28 NOV 2004 HIGHEST RN 790189-55-8  
DICTIONARY FILE UPDATES: 28 NOV 2004 HIGHEST RN 790189-55-8


TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more  
information enter HELP PROP at an arrow prompt in the file or refer  
to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

L1 STR




*same full file search*

NODE ATTRIBUTES:  
CONNECT IS E1 RC AT 1  
DEFAULT MLEVEL IS ATOM  
GGCAT IS LIN HIC AT 1  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 6

STEREO ATTRIBUTES: NONE  
L3 SCR 1830 AND 963 AND 1834  
L11 53 SEA FILE=REGISTRY SSS FUL L1 AND L3  
L34 STR



*n = 12*

*subset search done on  
this structure*

REP G1=(14-14) CH2  
NODE ATTRIBUTES:  
DEFAULT MLEVEL IS ATOM  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 7

STEREO ATTRIBUTES: NONE

L36 7 SEA FILE=REGISTRY SUB=L11 SSS FUL L34

100.0% PROCESSED 53 ITERATIONS

7 ANSWERS

SEARCH TIME: 00.00.01

=> fil capl; s l36

FILE 'CAPLUS' ENTERED AT 12:43:13 ON 30 NOV 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 30 Nov 2004 VOL 141 ISS 23

FILE LAST UPDATED: 28 Nov 2004 (20041128/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

L42 11 L36

*all refs to compd when n=12*

=> s l42 not l16

L43 6 L42 NOT L16

*previously printed*

=> d ibib ed abs hitstr l43 1-6

L43 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004:654293 CAPLUS

DOCUMENT NUMBER: 141:218241

TITLE: A more sensitive MS detector does not obviously lead to a more sensitive assay: Experiences with ES-285

AUTHOR(S): Stokvis, Ellen; Rosing, Hilde; Lopez-Lazaro, Luis; Schellens, Jan H. M.; Beijnen, Jos H.

CORPORATE SOURCE: Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Slotervaart Hospital, Amsterdam, 1066 EC, Neth.

SOURCE: Biomedical Chromatography (2004), 18(6), 403-407  
CODEN: BICHE2; ISSN: 0269-3879

PUBLISHER: John Wiley & Sons Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 13 Aug 2004

AB In this paper the transfer of an existing method for the quant. determination of the anticancer agent ES-285 in human plasma using liquid chromatog. tandem



mass spectrometry on an API 365 to an API 3000 mass spectrometer is described. The transfer appeared not to be straightforward. Problems arose resulting from carry-over and interferences. In addition, due to the expansion of the calibration range, data ought to be weighted with a different factor to increase the accuracy of the lower concns. After finding appropriate solns. for these problems, the lower limit of quantitation could be lowered from 10 to 1 ng/mL for ES-285 in human plasma. The usefulness and necessity of the modified assay was demonstrated by anal. of plasma samples from a patient receiving a low dosage of the drug.

IT 196497-48-0, ES-285


RL: ANT (Analyte); ANST (Analytical study)

(determination of antitumor agent ES-285 with two MS detectors having different sensitivities)

RN 196497-48-0 CAPLUS

CN 3-Octadecanol, 2-amino-, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004:191774 CAPLUS

DOCUMENT NUMBER: 141:320221

TITLE: Development and validation of a liquid chromatography-ultraviolet absorbance detection assay using derivatization for the novel marine anticancer agent ES-285·HCl [(2S,3R)-2-amino-3-octadecanol hydrochloride] and its pharmaceutical dosage form. [Erratum to document cited in CA140:099740]

AUTHOR(S): den Brok, Monique W. J.; Nuijen, Bastiaan; Miranda, Elena; Floriano, Pablo; Munt, Simon; Manzanares, Ignacio; Beijnen, Jos H.

CORPORATE SOURCE: The Netherlands Cancer Institute, Department of Pharmacy and Pharmacology, Slotervaart Hospital, Amsterdam, 1066 EC, Neth.

SOURCE: Journal of Chromatography, A (2004), 1033(1), 191  
CODEN: JCRAEY; ISSN: 0021-9673

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 10 Mar 2004

AB On page 257, column 2, line 4 from the bottom, "response range of 10.19-1.16 min" should read "response range of 1.19-11.16 min".

IT 196497-48-0, ES-285 378753-73-2


RL: ANT (Analyte); ANST (Analytical study)

(determination of ES-285 analogs by liquid chromatog. using phenylisothiocyanate (Erratum))

RN 196497-48-0 CAPLUS

CN 3-Octadecanol, 2-amino-, (2S,3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 378753-73-2 CAPLUS

CN 3-Octadecanol, 2-amino-, hydrochloride, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L43 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:846886 CAPLUS

DOCUMENT NUMBER: 140:99740

TITLE: Development and validation of a liquid chromatography-ultraviolet absorbance detection assay using derivatization for the novel marine anticancer agent ES-285·HCl [(2S,3R)-2-amino-3-octadecanol hydrochloride] and its pharmaceutical dosage form

AUTHOR(S): den Brok, Monique W. J.; Nuijen, Bastiaan; Miranda, Elena; Floriano, Pablo; Munt, Simon; Manzanares, Ignacio; Beijnen, Jos H.

CORPORATE SOURCE: The Netherlands Cancer Institute, Department of Pharmacy & Pharmacology, Slotervaart Hospital, Amsterdam, 1066 EC, Neth.

SOURCE: Journal of Chromatography, A (2003), 1020(2), 251-258  
CODEN: JCRAEY; ISSN: 0021-9673

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 29 Oct 2003

AB ES-285·HCl [(2S,3R)-2-amino-3-octadecanol hydrochloride] is a novel investigational anticancer agent, which has shown in vitro and in vivo cytotoxic activity against various tumor cell lines with selectivity for certain solid tumors. The pharmaceutical development of ES-285·HCl warranted the availability of an assay for the quantification and purity determination of ES-285·HCl active pharmaceutical ingredient (API) and its pharmaceutical dosage form. A liquid chromatog. method (LC) comprising of derivatization of ES-285·HCl with phenylisothiocyanate and UV-detection was developed. The method was found to be linear, precise and accurate. The assay also proved selectivity as determined by analyzing ES-285·HCl in combination with 15 analogs and in combination with hydroxypropyl-β-cyclodextrin, the excipient used in the lyophilized pharmaceutical dosage form. Stress testing showed that the degradation products were separated from the parent compound, confirming its stability indicating capacity. The method was found robust as determined with design of expts. (DoE), which made it possible to predict system suitability

responses in worst case exptl. conditions and to define criteria for system suitability testing.

IT 196497-48-0, ES-285 378753-73-2


RL: ANT (Analyte); ANST (Analytical study)

(determination of ES-285 analogs by liquid chromatog. using phenylisothiocyanate)

RN 196497-48-0 CAPLUS

CN 3-Octadecanol, 2-amino-, (2S,3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 378753-73-2 CAPLUS

CN 3-Octadecanol, 2-amino-, hydrochloride, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:427778 CAPLUS

DOCUMENT NUMBER: 139:374146

TITLE: Phenylisothiocyanate and dansyl chloride precolumn derivatizations for the high-performance liquid chromatography analysis of the antitumoral agent ES-285 in dog plasma

AUTHOR(S): Maraschiello, C.; Miranda, E.; Millan, E.; Floriano, P.; Vilageliu, J.

CORPORATE SOURCE: S.A.L., Centro de Investigacion y Desarrollo Aplicado, Pharmacokinetics and Analytical Chemistry Department, Barcelona, 08130, Spain

SOURCE: Journal of Chromatography, B: Analytical Technologies in the Biomedical and Life Sciences (2003), 791(1-2), 1-11

CODEN: JCBAAI; ISSN: 1570-0232

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 04 Jun 2003

AB Chromophore and fluorophore addition reactions involving phenylisothiocyanate (PITC) and dansyl chloride (DC) were optimized to adapt two high-performance liquid chromatog. (HPLC) procedures designed for the accurate determination of the novel antitumoral agent ES-285 in Beagle dog plasma.

ES-285 was reacted with PITC at 60 for 15 min in the presence of triethylamine. The dansyl derivative was obtained by reaction of ES-285 with dansyl chloride in a basic medium at 80 for 20 min. Both reactions also worked for ES-299, a compound structurally related to ES-285 which was used as internal standard. The treatment of ES-285 and ES-299 spiked plasma samples with a basic phosphate buffer and MeOH permitted the extraction of the drug from the matrix. The purification of the analytes was carried out by solid-phase extraction followed by precolumn derivatization with PITC and DC. The phenylisothiocyanate adducts were analyzed by isocratic HPLC with UV detection at 254 nm. The ES-285 and ES-299 derivs. were eluted from a C18 column at .apprx.6.9 and .apprx.8.1 min, resp. The eluent ACN-water (95:5, volume/volume) was delivered to the column at a flow-rate of 1 mL/min and the anal. was completed in 15 min. The dansyl derivs. were analyzed by a two-HPLC column system with fluorescence detection and gradient elution. The column temperature was maintained at 40. The anal. lasted 55 min with the elution of ES-285 and ES-299 derivs. at .apprx.35.2 and .apprx.37.9 min, resp. The PITC- and DC-based procedures were characterized by limits of quantification of 20 and 15 ng/mL, resp. Both procedures were validated according to the ICH and FDA guidelines. They were selective for ES-285 and provided accurate, precise and reproducible results. ES-299 was shown to be a suitable internal standard. The HPLC procedure involving derivatization with DC was more sensitive and permitted to process plasma sample vols. as low as 100 µL. The PITC-based procedure characterized by a quite similar LOQ permitted a higher throughput but implied the processing of a 500-µL plasma volume

IT 196497-48-0, ES 285


RL: ANT (Analyte); ANST (Analytical study)

(phenylisothiocyanate and dansyl chloride precolumn derivatizations for the high-performance liquid chromatog. anal. of the antitumoral agent ES-285 in dog plasma)

RN 196497-48-0 CAPLUS

CN 3-Octadecanol, 2-amino-, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1997:567049 CAPLUS

DOCUMENT NUMBER: 127:275864

TITLE: Dihydroceramide biology. Structure-specific metabolism and intracellular localization

AUTHOR(S): Kok, Jan Willem; Nikolova-Karakashian, Mariana; Klappe, Karin; Alexander, Chris; Merrill, Alfred H., Jr.

CORPORATE SOURCE: Department of Physiological Chemistry, University of Groningen, Groningen, 9713 AV, Neth.

SOURCE: Journal of Biological Chemistry (1997), 272(34), 21128-21136

CODEN: JBCHA3; ISSN: 0021-9258

PUBLISHER: American Society for Biochemistry and Molecular Biology

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 05 Sep 1997

AB This study utilized fluorescent analogs to characterize the intracellular transport and metabolism of dihydroceramide (DH-Cer), an intermediate in de novo sphingolipid biosynthesis. When 6-[N-(7-nitro-2,1,3-benzoxadiazol-4-yl)aminohexanoyl-DH-Cer (C6-NBD-DH-Cer) was incubated with HT29, NRK, BHK, or HL-60 cells, it was efficiently converted to dihydrosphingomyelin and dihydroglucosylceramide, and a number of other sphingolipids, with the nature of the products depending on the cell line. In addition, complex sphingolipids were formed that contained a desatd. (sphingosine) backbone, indicating that DH-Cer (and/or its metabolites) were substrates for the desaturase(s) that introduce the 4,5-trans double bond. Based on the kinetics and inhibitor studies, double bond addition did not appear to occur with the complex sphingolipids directly, but rather, during turnover and resynthesis. The conversion of C6-NBD-DH-Cer to more complex sphingolipids was highly stereoselective for the natural D,erythro isomer of C6-NBD-DH-Cer. Interestingly, the stereochem. of the sphingoid base backbone also affected the localization of fluorescent sphingolipids: the D,erythro species appeared in the Golgi apparatus, whereas other stereo-isomers accumulated in the endoplasmic reticulum. In addition to C6-NBD-Cer and C6-NBD-DH-Cer, C6-NBD-4-D-hydroxy-DH-Cer gave rise to formation of complex sphingolipids and localized at the Golgi apparatus. These studies indicate that dihydroceramide is used as the initial backbone of complex (glyco)sphingolipids, perhaps to avoid build up to ceramide as an intermediate since this is such a potent bioactive compound. The stereoselectivity in transport and metabolism suggests that trafficking of ceramide is protein-directed rather than simply a consequence of vesicular membrane flow.

IT 196497-48-0


RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(metabolic pathways for conversion of dihydroceramides to ceramides and more complex sphingolipids and their intracellular localization)

RN 196497-48-0 CAPLUS

CN 3-Octadecanol, 2-amino-, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L43 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1962:74587 CAPLUS

DOCUMENT NUMBER: 56:74587

ORIGINAL REFERENCE NO.: 56:14556g-i

TITLE: Chromatography of the lipid bases on paper impregnated with silicic acid

AUTHOR(S): Palameta, B.; Prostenik, M.

CORPORATE SOURCE: Inst. Ruder Boskovic, Zagreb, Yugoslavia

SOURCE: Croatica Chemica Acta (1961), 33, 133-5

CODEN: CCACAA; ISSN: 0011-1643

DOCUMENT TYPE: Journal


LANGUAGE: English

ED Entered STN: 22 Apr 2001

AB Rf values for several C18 and C20 lipid bases in iso-Bu<sub>2</sub>CO-AcOH-H<sub>2</sub>O (40:25:5) on silicic acid-impregnated paper by ascending technique (15-20

hrs.) were: C18-sphingine (0.34); 2-amino-3-hydroxyoctadecane (0.32); C18-sphingosine (0.29); 2-amino-3-octadecanone-HBr (0.38); 2,3-diaminooctadecane (0.25); C20sphingine (0.35); 4-amino-5-hydroxyeicosane (0.42); 3-amino-4-hydroxy-2-methylnonadecane (0.42); C20-phytosphingosine (0.23); 4-amino-5-eicosanone-HBr (0.49); 3-amino-2-methyl-4-nonadecanone-HBr (0.49); necrosamine (0.29); 3,4-diamino-2-methylnonadecane (0.29); C20-phytosphingosine anhydro base (0.35).

IT 97014-46-5, 3-Octadecanol, 2-amino-  
(chromatography of)  
RN 97014-46-5 CAPLUS  
CN 3-Octadecanol, 2-amino- (7CI) (CA INDEX NAME)



=> fil uspatf; s l36  
FILE 'USPATFULL' ENTERED AT 12:43:28 ON 30 NOV 2004  
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)  
  
FILE COVERS 1971 TO PATENT PUBLICATION DATE: 30 Nov 2004 (20041130/PD)  
FILE LAST UPDATED: 30 Nov 2004 (20041130/ED)  
HIGHEST GRANTED PATENT NUMBER: US6826778  
HIGHEST APPLICATION PUBLICATION NUMBER: US2004237163  
CA INDEXING IS CURRENT THROUGH 30 Nov 2004 (20041130/UPCA)  
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 30 Nov 2004 (20041130/PD)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2004  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2004

>>> USPAT2 is now available. USPATFULL contains full text of the <<<  
>>> original, i.e., the earliest published granted patents or <<<  
>>> applications. USPAT2 contains full text of the latest US <<<  
>>> publications, starting in 2001, for the inventions covered in <<<  
>>> USPATFULL. A USPATFULL record contains not only the original <<<  
>>> published document but also a list of any subsequent <<<  
>>> publications. The publication number, patent kind code, and <<<  
>>> publication date for all the US publications for an invention <<<  
>>> are displayed in the PI (Patent Information) field of USPATFULL <<<  
>>> records and may be searched in standard search fields, e.g., /PN, <<<  
>>> /PK, etc. <<<

>>> USPATFULL and USPAT2 can be accessed and searched together <<<  
>>> through the new cluster USPATALL. Type FILE USPATALL to <<<  
>>> enter this cluster. <<<  
>>> <<<  
>>> Use USPATALL when searching terms such as patent assignees, <<<  
>>> classifications, or claims, that may potentially change from <<<  
>>> the earliest to the latest publication. <<<

This file contains CAS Registry Numbers for easy and accurate  
substance identification.

L44 4 L36

=> s l44 not l19

L45 0 L44 NOT L19

*previously  
printed*

=> fil biosis toxcenter anabs; s l36  
FILE 'BIOSIS' ENTERED AT 12:43:44 ON 30 NOV 2004  
Copyright (c) 2004 The Thomson Corporation.

FILE 'TOXCENTER' ENTERED AT 12:43:44 ON 30 NOV 2004  
COPYRIGHT (C) 2004 ACS

FILE 'ANABSTR' ENTERED AT 12:43:44 ON 30 NOV 2004  
COPYRIGHT (c) 2004 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

L46 11 L36

=> s l46 not l25

L48 0 L46 NOT (L25)

*previously  
printed*

=> fil IMSDRUGNEWS, IMSRESEARCH, PROUSDDR; s l36  
FILE 'IMSDRUGNEWS' ENTERED AT 12:44:17 ON 30 NOV 2004  
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'IMSRESEARCH' ENTERED AT 12:44:17 ON 30 NOV 2004  
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'PROUSDDR' ENTERED AT 12:44:17 ON 30 NOV 2004  
COPYRIGHT (C) 2004 Prous Science

L49 4 L36

=> s l49 not l28

L50 0 L49 NOT (L28)

*previously  
printed*

=> fil beil

FILE 'BEILSTEIN' ENTERED AT 12:44:43 ON 30 NOV 2004  
COPYRIGHT (c) 2004 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften  
licensed to Beilstein GmbH and MDL Information Systems GmbH

FILE RELOADED ON OCTOBER 20, 2002  
FILE LAST UPDATED ON NOVEMBER 3, 2004

FILE COVERS 1771 TO 2004.

\*\*\* FILE CONTAINS 9,073,068 SUBSTANCES \*\*\*

>>>PLEASE NOTE: Reaction Data and substance data are stored in  
separate documents and can not be searched together in one query.  
Reaction data for BEILSTEIN compounds may be displayed  
immediately with the display codes PRE (preparations) and REA  
(reactions). A substance answer set retrieved after the search  
for a chemical name, a compounds with available reaction  
information by combining with PRE/FA, REA/FA or more generally  
with RX/FA. The BEILSTEIN Registry Number (BRN) is the link  
between a BEILSTEIN compound and belonging reactions. For mo  
detailed reaction searches BRNs can be searched as reaction  
partner BRNs Reactant BRN (RX.RBRN) or Product BRN (RX.PBRN).<<<

>>> FOR SEARCHING PREPARATIONS SEE HELP PRE <<<

\*\*\*\*\*  
\* PLEASE NOTE THAT THERE ARE NO FORMATS FREE OF COST. \*  
\* SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR SET NOTICE \*  
\* ARE BASED ON THE HIGHEST PRICE CATEGORY. THEREFORE; THESE \*

\* ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS. \*  
\* FOR PRICE INFORMATION SEE HELP COST \*  
\*\*\*\*\*

## NEW

- \* PATENT NUMBERS (PN) AND BABS ACCESSION NUMBERS (BABSAN) CAN NOW BE SEARCHED, SELECTED AND TRANSFERRED.
- \* NEW DISPLAY FORMATS ALLREF, ALLP AND BABSAN SHOW ALL REFERENCES, ALL PATENT REFERENCES, OR ALL BABS ACCESSION NUMBERS FOR A COMPOUND AT A GLANCE.

=> s l36

L52 4 L36

=>d ide pre l52 1-4

FILE 'BEILSTEIN' ENTERED AT 12:46:46 ON 30 NOV 2004  
COPYRIGHT (c) 2004 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften  
licensed to Beilstein GmbH and MDL Information Systems GmbH

FILE RELOADED ON OCTOBER 20, 2002


FILE LAST UPDATED ON NOVEMBER 3, 2004

L52 ANSWER 1 OF 4 BEILSTEIN COPYRIGHT 2004 BEILSTEIN MDL on STN

Beilstein Records (BRN):	3913199
Beilstein Pref. RN (BPR):	109555-73-9
CAS Reg. No. (RN):	<b>109555-73-9</b>
Chemical Name (CN):	Ds-threo-2-amino-octadecan-3-ol; hydrochloride
Fragm. Molec. Formula (FMF):	C18 H39 N O , Cl H
Molecular Formula (MF):	C18 H39 N O . Cl H
Molecular Weight (MW):	285.51, 36.46
Fragment BRN (FBRN):	1722975, 1098214
Lawson Number (LN):	3180
File Segment (FS):	Stereo compound
Compound Type (CTYPE):	acyclic
Constitution ID (CONSID):	3586416
Tautomer ID (TAUTID):	3823592
Beilstein Citation (BSO):	4-04-00-01825
Entry Date (DED):	1991/02/26
Update Date (DUPD):	1991/02/26

CM 1

FBRN 1722975  
FMF C18 H39 N O





CM 2

FBRN 1098214

FMF Cl H

## Field Availability:

Code	Name	Occurrence
BRN	Beilstein Records	1
BPR	Beilstein Preferred RN	1
RN	CAS Registry Number	1
CN	Chemical Name	1
FMF	Fragment Molecular Formula	2
MF	Molecular Formula	1
FW	Formular Weight	2
FBRN	Fragment BRN	2
LN	Lawson Number	1
FS	File Segment	1
CTYPE	Compound Type	1
CONSID	Constitution ID	1
TAUTID	Tautomer ID	1
BSO	Beilstein Citation	1
ED	Entry Date	1
UPD	Update Date	1
MP	Melting Point	1
ORP	Optical Rotatory Power	1


L52 ANSWER 2 OF 4 BEILSTEIN COPYRIGHT 2004 BEILSTEIN MDL on STN

Beilstein Records (BRN): 3913198  
Beilstein Pref. RN (BPR): 109555-73-9  
CAS Reg. No. (RN): **109555-73-9**  
Chemical Name (CN): D-erythro-2-amino-octadecan-3-ol;  
hydrochloride  
Fragm. Molec. Formula (FMF): C18 H39 N O , Cl H  
Molecular Formula (MF): C18 H39 N O . Cl H  
Molecular Weight (MW): 285.51, 36.46  
Fragment BRN (FBRN): 1722974, 1098214  
Lawson Number (LN): 3180  
File Segment (FS): Stereo compound  
Compound Type (CTYPE): acyclic  
Constitution ID (CONSID): 3586416  
Tautomer ID (TAUTID): 3823591  
Beilstein Citation (BSO): 4-04-00-01825  
Entry Date (DED): 1991/02/26  
Update Date (DUPD): 1991/02/26

CM 1

FBRN 1722974

FMF C18 H39 N O



CM 2

FBRN 1098214


FMF C1 H

## Field Availability:

Code	Name	Occurrence
BRN	Beilstein Records	1
BPR	Beilstein Preferred RN	1
RN	CAS Registry Number	1
CN	Chemical Name	1
FMF	Fragment Molecular Formula	2
MF	Molecular Formula	1
FW	Formular Weight	2
FBRN	Fragment BRN	2
LN	Lawson Number	1
FS	File Segment	1
CTYPE	Compound Type	1
CONSID	Constitution ID	1
TAUTID	Tautomer ID	1
BSO	Beilstein Citation	1
ED	Entry Date	1
UPD	Update Date	1
MP	Melting Point	1
ORP	Optical Rotatory Power	1

L52 ANSWER 3 OF 4 BEILSTEIN COPYRIGHT 2004 BEILSTEIN MDL on STN

Beilstein Records (BRN): 1722975  
Beilstein Pref. RN (BPR): 97014-46-5  
CAS Reg. No. (RN): **97014-46-5**  
Chemical Name (CN): (2S,3S)-2-amino-octadecan-3-ol  
Autonom Name (AUN): 2-amino-octadecan-3-ol  
Molec. Formula (MF): C18 H39 N O  
Molecular Weight (MW): 285.51  
Lawson Number (LN): 3180  
File Segment (FS): Stereo compound  
Compound Type (CTYPE): acyclic  
Constitution ID (CONSID): 1642921  
Tautomer ID (TAUTID): 1699386  
Beilstein Citation (BSO): 4-04-00-01825  
Entry Date (DED): 1989/02/27  
Update Date (DUPD): 1993/09/01



## Field Availability:

Code	Name	Occurrence
=====	=====	=====
BRN	Beilstein Records	1
BPR	Beilstein Preferred RN	1
RN	CAS Registry Number	1
CN	Chemical Name	1
AUN	Autonomname	1
MF	Molecular Formula	1
FW	Formular Weight	1
LN	Lawson Number	1
FS	File Segment	1
CTYPE	Compound Type	1
CONSID	Constitution ID	1
TAUTID	Tautomer ID	1
BSO	Beilstein Citation	1
ED	Entry Date	1
UPD	Update Date	1

This substance also occurs in Reaction Documents:

Code	Name	Occurrence
=====	=====	=====
RX	Reaction Documents	3
RXREA	Substance is Reaction Reactant	1
RXPRO	Substance is Reaction Product	2

## Reaction:

RX

Reaction ID (.ID): 7978673

Reactant BRN (.RBRN): 1718733, 3709289

Reactant (.RCT): platinum, ethanol, (S)-2-amino-octadecan-3-one; hydrobromide

Product BRN (.PBRN): 1722974, 1722975

Product (.PRO): (2S,3R)-2-amino-octadecan-3-ol, (2S,3S)-2-amino-octadecan-3-ol

No. of React. Details (.NVAR): 1

## Reaction Details:

RX

Reaction RID (.RID): 7978673.1

Reaction Classification (.CL): Chemical behaviour

Other Conditions (.COND): Hydrogenation

Note(s) (.COM): Handbook

## Reference(s):

1. Prostenik; Alaupovic, Croat.Chem.Acta, CODEN: CCACAA, 29, <1957>, 393, 400

## Reaction:

RX

Reaction ID (.ID):	539532
Reactant BRN (.RBRN):	3709289
Reactant (.RCT):	(S)-2-amino-octadecan-3-one; hydrobromide
Product BRN (.PBRN):	1722975, 1722974
Product (.PRO):	(2S,3S)-2-amino-octadecan-3-ol, (2S,3R)-2-amino-octadecan-3-ol
No. of React. Details (.NVAR):	2

## Reaction Details:

RX


Reaction RID (.RID):	539532.1
Reaction Classification (.CL):	Preparation
Reagent (.RGT):	platinum, ethanol
Other Conditions (.COND):	Hydrogenation
Note(s) (.COM):	Handbook
Reference(s):	
1. Prostenik; Alaupovic, Croat.Chem.Acta, CODEN: CCACAA, 29, <1957>, 393, 400	

RX

Reaction RID (.RID):	539532.2
Reaction Classification (.CL):	Preparation
Reagent (.RGT):	platinum, ethanol
Note(s) (.COM):	Handbook
Reference(s):	
1. Prostenik; Alaupovic, Croat.Chem.Acta, CODEN: CCACAA, 29, <1957>, 393, 400	

## L52 ANSWER 4 OF 4 BEILSTEIN COPYRIGHT 2004 BEILSTEIN MDL on STN

Beilstein Records (BRN):	1722974
Beilstein Pref. RN (BPR):	97014-46-5
CAS Reg. No. (RN):	<b>97014-46-5</b>
Chemical Name (CN):	(2S,3R)-2-amino-octadecan-3-ol
Autonom Name (AUN):	2-amino-octadecan-3-ol
Molec. Formula (MF):	C18 H39 N O
Molecular Weight (MW):	285.51
Lawson Number (LN):	3180
File Segment (FS):	Stereo compound
Compound Type (CTYPE):	acyclic
Constitution ID (CONSID):	1642921
Tautomer ID (TAUTID):	1699385
Beilstein Citation (BSO):	4-04-00-01825
Entry Date (DED):	1989/02/27
Update Date (DUPD):	2003/10/23



## Field Availability:

Code	Name	Occurrence
=====	=====	=====
BRN	Beilstein Records	1
BPR	Beilstein Preferred RN	1
RN	CAS Registry Number	1
CN	Chemical Name	1
AUN	Autonomname	1
MF	Molecular Formula	1
FW	Formular Weight	1
LN	Lawson Number	1
FS	File Segment	1
CTYPE	Compound Type	1
CONSID	Constitution ID	1
TAUTID	Tautomer ID	1
BSO	Beilstein Citation	1
ED	Entry Date	1
UPD	Update Date	1

This substance also occurs in Reaction Documents:

Code	Name	Occurrence
=====	=====	=====
RX	Reaction Documents	6
RXREA	Substance is Reaction Reactant	2
RXPRO	Substance is Reaction Product	4

## Reaction:

RX

Reaction ID (.ID): 7978673

Reactant BRN (.RBRN): 1718733, 3709289

Reactant (.RCT): platinum, ethanol, (S)-2-amino-octadecan-3-one; hydrobromide

Product BRN (.PBRN): 1722974, 1722975

Product (.PRO): (2S,3R)-2-amino-octadecan-3-ol, (2S,3S)-2-amino-octadecan-3-ol

No. of React. Details (.NVAR): 1

## Reaction Details:

RX

Reaction RID (.RID): 7978673.1

Reaction Classification (.CL): Chemical behaviour

Other Conditions (.COND): Hydrogenation

Note(s) (.COM): Handbook

Reference(s):

1. Prostenik; Alaupovic, Croat.Chem.Acta, CODEN: CCACAA, 29, <1957>, 393, 400

## Reaction:

RX  
Reaction ID (.ID): 7978672  
Reactant BRN (.RBRN): 1696894, 102391, 3709289  
Reactant (.RCT): lithium alanate, diethyl ether,  
tetrahydrofuran, (S)-2-amino-octadecan-3-one; hydrobromide  
Product BRN (.PBRN): 1722974  
Product (.PRO): (2S,3R)-2-amino-octadecan-3-ol  
No. of React. Details (.NVAR): 1

## Reaction Details:

RX  
Reaction RID (.RID): 7978672.1  
Reaction Classification (.CL): Chemical behaviour  
Note(s) (.COM): Handbook  
Reference(s):  
1. Prostenik; Alaupovic, Croat.Chem.Acta, CODEN: CCACAA, 29, <1957>, 393, 400

## Reaction:

RX  
Reaction ID (.ID): 539532  
Reactant BRN (.RBRN): 3709289  
Reactant (.RCT): (S)-2-amino-octadecan-3-one; hydrobromide  
Product BRN (.PBRN): 1722975, 1722974  
Product (.PRO): (2S,3S)-2-amino-octadecan-3-ol,  
(2S,3R)-2-amino-octadecan-3-ol  
No. of React. Details (.NVAR): 2

## Reaction Details:

RX  
Reaction RID (.RID): 539532.1  
Reaction Classification (.CL): Preparation  
Reagent (.RGT): platinum, ethanol  
Other Conditions (.COND): Hydrogenation  
Note(s) (.COM): Handbook  
Reference(s):  
1. Prostenik; Alaupovic, Croat.Chem.Acta, CODEN: CCACAA, 29, <1957>, 393, 400

RX  
Reaction RID (.RID): 539532.2  
Reaction Classification (.CL): Preparation  
Reagent (.RGT): platinum, ethanol  
Note(s) (.COM): Handbook  
Reference(s):  
1. Prostenik; Alaupovic, Croat.Chem.Acta, CODEN: CCACAA, 29, <1957>, 393, 400

## Reaction:

RX  
Reaction ID (.ID): 539531  
Reactant BRN (.RBRN): 3709289  
Reactant (.RCT): (S)-2-amino-octadecan-3-one; hydrobromide  
Product BRN (.PBRN): 1722974  
Product (.PRO): (2S,3R)-2-amino-octadecan-3-ol  
No. of React. Details (.NVAR): 1

## Reaction Details:

RX  
Reaction RID (.RID): 539531.1

Reaction Classification (.CL): Preparation  
Reagent (.RGT): lithium alanate, diethyl ether, THF  
Note(s) (.COM): Handbook  
Reference(s):  
1. Prostenik; Alaupovic, Croat.Chem.Acta, CODEN: CCACAA, 29, <1957>, 393, 400

=> fil cao; s l36

FILE 'CAOLD' ENTERED AT 12:45:15 ON 30 NOV 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966

FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

L53

2 L36

*all refs for compd when n=12*

=>d iall hitstr l53 1-2

L53 ANSWER 1 OF 2 CAOLD COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: CA56:14556g CAOLD

TITLE: chromatography of the lipid bases on paper impregnated with silicic acid


AUTHOR NAME: Palameta, B.; Prostenik, M.

INDEX TERM: 504-34-7 506-02-5 3625-50-1 38217-16-2 94377-06-7  
94677-73-3 94873-51-5 94873-52-6 97014-46-5  
97014-78-3

IT 97014-46-5

RN 97014-46-5 CAOLD

CN 3-Octadecanol, 2-amino- (7CI) (CA INDEX NAME)



L53 ANSWER 2 OF 2 CAOLD COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: CA53:1131g CAOLD

TITLE: application of the asymmetric synthesis in the determination of the configuration of amino alcs. and diamines with two adjacent asymmetric C atoms

AUTHOR NAME: Prostenik, M.; Alaupovic, P.


INDEX TERM: 94377-06-7 102013-40-1 103043-93-2 103044-87-7 103267-90-9  
103387-52-6 108367-54-0 109254-74-2 109555-73-9

113751-42-1 113860-71-2

IT 109555-73-9

RN 109555-73-9 CAOLD

CN 3-Octadecanol, 2-amino-, hydrochloride (6CI) (CA INDEX NAME)



● HCl

=&gt; fil hom

FILE 'HOME' ENTERED AT 12:47:11 ON 30 NOV 2004